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Summary
The mitochondrial disulfide relay system of Mia40 and Erv1/ALR facilitates import of the small
Translocase of the Inner Membrane (Tim) proteins and cysteine rich proteins. A chemical screen
identified small molecules that inhibit Erv1 oxidase activity, thereby facilitating dissection of the
disulfide relay system in yeast and vertebrate mitochondria. One molecule, MitoBloCK-6,
attenuated the import of Erv1 substrates into yeast mitochondria and inhibited oxidation of Tim13
and Cmc1 in in vitro reconstitution assays. In addition, MitoBloCK-6 revealed an unexpected role
for Erv1 in the carrier import pathway, namely transferring substrates from the Translocase of the
Outer Membrane (TOM) complex onto the small Tim complexes. Cardiac development was
impaired in MitoBloCK-6 exposed zebrafish embryos. Finally, MitoBloCK-6 induced apoptosis
via cytochrome c release in human embryonic stem cells (hESCs) but not in differentiated cells,
suggesting an important role for ALR in hESC homeostasis.
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The mitochondrion has translocons of the outer membrane (TOM) and inner membrane
(TIM) to import proteins from the cytosol. Proteins with a typical N-terminal targeting
sequence are imported via the TIM23 pathway, whereas polytopic inner membrane proteins
use the TIM22 import pathway (Chacinska et al., 2009; Mokranjac and Neupert, 2009). In
contrast, most of the proteins imported into the intermembrane space (IMS) lack a
mitochondrial targeting sequence and employ diverse routes for mitochondrial import
(Herrmann and Hell, 2005).
A recently identified pathway in the IMS mediates oxidation of imported proteins that
require disulfide bonds to acquire their native conformation (Deponte and Hell, 2009;
Koehler and Tienson, 2009; Riemer et al., 2011; Sideris and Tokatlidis, 2010), such as the
small Tim proteins and proteins with a twin CX9C motif (Cavallaro, 2010). In the small Tim
proteins, the proximal N-terminal cysteine residues serve as internal targeting sequences that
are recognized by the IMS oxidoreductase Mia40 (Milenkovic et al., 2009; Sideris et al.,
2009), which functions as a receptor to mediate translocation across the outer membrane
(Chacinska et al., 2004). Mia40 contains a redox-active cysteine pair that is maintained in an
oxidized state by the sulfhydryl oxidase Erv1 (Tienson et al., 2009). As the imported protein
substrate is oxidized, electrons are passed from Mia40 to Erv1, followed by transfer to
molecular oxygen or cytochrome c (cyt c) (Bien et al., 2010; Dabir et al., 2007).
Subsequently, cyt c can be reoxidized by cyt c oxidase of the respiratory chain (Bien et al.,
2010) or by cyt c peroxidase (Dabir et al., 2007). Thus, Mia40 and Erv1 constitute a
mitochondrial disulfide relay system that is also evolutionarily conserved.
Erv1 belongs to the Erv/ALR sulfhydryl oxidase family and homologous proteins are found
in the endoplasmic reticulum (Erv2) of yeast, in the extracellular environment (Quiescin
sulfhydryl oxidase, QSOX), and in the poxvirus family (E10R) (Gerber et al., 2001;
Senkevich et al., 2002; Thorpe et al., 2002). In addition to protein translocation, the role of
Erv1 in various cellular pathways is exemplified by a number of defects observed in cells
that lack functional Erv1 protein. For example, Erv1 is required for the maturation of
cytosolic iron-sulfur cluster containing proteins (Lange et al., 2001). In erv1 mutant yeast,
heme maturation is impaired (Dabir et al., 2007). Also, mutations in mammalian Erv1
homolog, ALR, result in an autosomal-recessive myopathy (Di Fonzo et al., 2009), and ALR
has an essential pro-survival role in the maintenance of murine ESCs (Todd et al., 2010b)
and in the regeneration of Drosophila imaginal discs (McClure et al., 2008).
Erv1 has several key functions in the IMS, necessitating the characterization of its homolog,
ALR, to uncover basic mechanisms in mitochondrial assembly in vertebrate systems.
Because Erv1 donates electrons to cyt c, Erv1/ALR may have a central role in apoptotic
pathways that lead to cyt c release (Dabir et al., 2007). Classically, mitochondrial protein
import has been studied using yeast genetics and biochemical assays. However, new
approaches are needed to elucidate disease mechanisms and dissect essential functions in
mammalian cells. Here we report a small molecule screening approach to identify Erv1
inhibitors, with the goal of developing a set of probes that can modulate the pathway quickly
and recapitulate disease phenotypes. We have taken advantage of the previously developed
in vitro Amplex Red assay for monitoring Erv1 activity to identify inhibitors (Dabir et al.,
2007). Our results indicate that the small drug-like inhibitor characterized here is specific for
Erv1/ALR and can be used to reveal normal functions and disease mechanisms in
mammalian mitochondria.
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A Chemical Screen to Identify Inhibitors of Erv1 Oxidase Activity
We previously developed an assay to test the sulfhydryl oxidase activity of recombinant
Erv1 protein based on the oxidation of a non-physiologic substrate, DTT, which produces
hydrogen peroxide (H2O2) (Dabir et al., 2007). H2O2 production was measured using a
standard fluorometric assay with Amplex Red and horseradish peroxidase (HRP). The assay
was adapted in high throughput format and a chemical screen was conducted on an
integrated robotic system with plate scheduling (Figure S1A). Briefly, diversity oriented
commercial libraries of 50,000 drug-like compounds from Chembridge (Lumsden et al.,
2007; Webb, 2005), Kwon (Castellano et al., 2007), and Asinex (Lumsden et al., 2007) at 10
μM concentration were screened for inhibition of Erv1 activity. Erv1 (10 μM) was aliquoted
into 384-well plates followed by compound addition with robotic pinning into the assay
wells. DMSO (1%, vehicle) was included in several plate columns as a carrier control with
the pinned compounds. As a negative control, 10 μM catalytically inactive Erv1
(Erv1C133S) was also aliquoted into several plate columns. Incubation of the pinned
compounds with Erv1 for 1 h at 25°C was followed by addition of Amplex Red-HRP and
then DTT (20 μM) to initiate the oxidase assay. After 12 min, the reaction was in the kinetic
linear range and a high signal-to-noise ratio was achieved. Fluorescence intensity was
measured and reactions that were inhibited by more than 50% were picked as potential Erv1
inhibitors and selected for secondary analysis. In total, 184 primary candidate inhibitors
were identified (Figure S1B). 40 plates were processed with a Z’ greater than 0.8 across the
screen, indicating that the screen was consistent and robust.
To eliminate false positives, a counter screen was used to test whether the small molecule
compounds directly inhibited the Amplex Red-HRP assay. H2O2 (800 nM) was reacted with
Amplex Red-HRP in the presence of the small molecules; this is the approximate amount of
H2O2 that was produced by Erv1 during the assay. Those compounds that did not inhibit the
Amplex Red assay directly and showed > 50% inhibition of Erv1 activity (~29 compounds)
were selected for additional characterization and designated as “MitoBloCK” compounds
(Mitochondrial protein import Blockers from the Carla Koehler lab) based on their potential
to inhibit Erv1 activity. Of these potential “lead” inhibitors, MitoBloCK-6 was chosen for
additional analysis. Figure S1C verifies that MitoBloCK-6 does not directly hinder the
Amplex Red-HRP reaction.
MitoBloCK-6 Inhibits Erv1 Activity in vitro
MitoBloCK-6 is 2,4-dichloro-6-((((phenylamino)phenyl)imino)methyl)phenol) from the
Chembridge library (Figure 1A), consisting of a 3,5-dichlorosalicylaldehyde derivative.
Upon reordering, MitoBloCK-6 showed the same Erv1 inhibitory activity as the original
aliquot from the Chembridge library. The IC50 for MitoBloCK-6 that inhibited Erv1 oxidase
activity in the in vitro Amplex Red-HRP assay was 900 nM (Figure 1B). We also tested
MitoBloCK-6 as an inhibitor of ALR (Farrell and Thorpe, 2005) and the yeast paralog in the
endoplasmic reticulum, Erv2 (Gross et al., 2002) using the in vitro Amplex Red-HRP assay.
The IC50 for MitoBloCK-6 inhibiting ALR and Erv2 was 700 nM and 1.4 μM, respectively
(unpublished data).
To determine whether MitoBloCK-6 generally impaired redox active enzymes, we
investigated the oxidative folding properties of protein disulfide isomerase (PDI).
MitoBloCK-6 did not inhibit the ability of PDI to reduce insulin (Figure S1D). Because
MitoBloCK-6 may potentially hinder FAD-containing enzymes, succinate dehydrogenase
activity of the mitochondrial respiratory chain was measured in the presence of
MitoBloCK-6 (Figure S1E). Isolated mitochondria were incubated in a Clarke-type oxygen
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electrode and oxygen consumption was measured with succinate addition. The oxygen
consumption rate was indicative of well-coupled mitochondria and subsequent addition of
DMSO vehicle or MitoBloCK-6 did not alter the oxygen consumption rate. As controls,
succinate dehydrogenase activity was disrupted with the inhibitor malonate, and CCCP
addition indicated that respiring mitochondria could be uncoupled. Because a 3,5-
dichlorosalicylaldehyde is a potential degradation product of MitoBloCK-6, and the 3,5-
dichlorosalicylaldehyde moiety may instead inhibit Erv1 (Doorn and Petersen, 2003),
commercially available 3,5-dichlorosalicylaldehyde replaced MitoBloCK-6 in the in vitro
Amplex Red-HRP assay (Figure 1C). The addition of 100 μM 3, 5-dichlorosalicylaldehyde
did not inhibit Erv1 activity. We assessed MitoBloCK-6 stability in our screening conditions
at pH 6.5 and 7.4 using liquid chromatography-mass spectrometry (LC-MS) analysis (Figure
S2A). Analysis at pH 3.4 was also included, because an acidic pH favors hydrolysis of the
imine linkage to release the 3,5-dichlorosalicylaldehyde (Kirdant et al., 2011). MitoBloCK-6
was stable over this pH range as supported by a similar retention time (3.03 min) and a
constant area under the curve in the LC-MS analysis (Figure S2A).
Because aldehydes covalently modify lysine residues in proteins by forming a Schiff base
(Volkmann et al., 2011; Yamagata et al., 1993), we tested whether a potential aldehyde
derived from MitoBloCK-6 covalently modified Erv1 using mass spectrometry (Figure
S2B). The addition of 75 μM 3, 5-dichlorosalicylaldehyde to 25 μM Erv1 yielded a
spectrum with a single, minor peak at 175 Da, which corresponds to a small amount (<5%)
of the 3, 5-dichlorosalicylaldehyde bonding to one position in Erv1; in contrast, most of the
Erv1 migrated as the unmodified protein, indicating that the lysine residues in Erv1 are not
highly reactive. Using lysozyme as a control protein, a small fraction of 3, 5-
dichlorosalicylaldehyde again attached covalently, but most of the lysozyme was
unmodified (Figure S2C). MitoBloCK-6 (75 μM) addition to Erv1 (25 μM) generated a
spectrum in which a small fraction (<3%) of MitoBloCK-6 likely degraded to 3, 5-
dichlorosalicylaldehyde that covalently modified Erv1 (Figure S2B); MitoBloCK-6 was
specific for Erv1, because the lysozyme spectrum lacked a similar peak that was shifted by
175 Da and additional peaks were not detected (Figure S2C). As a control for the assay,
formaldehyde treatment to lysozyme yielded a spectrum in which unmodified lysozyme was
replaced with lysozyme bonded with at least 7 to 9 formaldehyde groups (Figure S2C).
Thus, MitoBloCK-6 is a stable compound that does not markedly bond to Erv1.
MitoBloCK-6 Inhibits Erv1-Dependent Import in Mitochondria
The import of Erv1 substrates was tested with an in organello import assay. Substrates
included twin CX9C proteins (Mia40, Cmc1, Cox19, and Cox17), twin CX3C protein Tim8,
and Erv1 (Figure 2, S3) (Hofmann et al., 2005; Horn et al., 2008; Riemer et al., 2011;
Terziyska et al., 2007). Energized mitochondria were preincubated with 20 to 50 μM
MitoBloCK-6 or 1% DMSO for 15 min, followed by the addition of the radiolabeled
substrate. A time course assay was performed and aliquots were removed and treated with
protease to remove non-imported precursors. Import of the twin CX9C proteins and Erv1
was strongly decreased, whereas the import of Tim8 was impaired by 40% upon treatment
with MitoBloCK-6 compared to import in presence of 1% DMSO. We also investigated the
import of additional substrates, Tim23 and AAC of the TIM22 import pathway and Su9-
DHFR, cyt b2-DHFR, and Hsp60 of the TIM23 import pathway (Figure 3, S3). At 20 μM,
the import of Tim23 and AAC was decreased by approximately 50% (Figure 3A,B),
whereas the import of TIM23 substrates was not impaired even with 50 μM MitoBloCK-6
(Figure 3C, S3A,B).
Given that Erv1 played a role in the import of TIM22 substrates, we investigated the import
of AAC using blue-native (BN) gel analysis (Figure 3D). Previous studies have defined the
steps of AAC translocation from the cytosol to the inner membrane using mutants and
Dabir et al. Page 4













biochemical manipulations (Curran et al., 2002; Ryan et al., 1999; Truscott et al., 2002).
Specifically, AAC accumulates with the TOM machinery in a 500 kDa complex in the
tim10-2 mutant or in the absence of ATP, and then is passed to the Tim9-Tim10 complex;
the mature form of AAC subsequently assembles as a dimer in a 90 kDa complex in the
inner membrane. After importing AAC in the presence MitoBloCK-6 or control DMSO, the
mitochondria were solubilized in 1% digitonin and separated on BN gels followed by
autoradiography. In the presence of DMSO, AAC accumulated in the 90 kDa complex,
which is indicative of an assembled AAC dimer (AAC2). Moreover, the AAC dimer was
protected from exogenous protease, verifying that AAC translocated to the inner membrane.
In contrast, the addition of MitoBloCK-6 resulted in AAC accumulation in a 500 kDa
complex with the TOM complex (Figure 3D) and this AAC intermediate was sensitive to
protease, confirming localization at the outer membrane. Analysis with MitoBloCK-6
supports a role for Erv1 in transferring AAC from the TOM complex to the Tim9-Tim10
complex in the intermembrane space. Therefore, in addition to the cysteine-rich substrates,
Erv1 plays a key role in the TIM22 import pathway.
To confirm specificity of MitoBloCK-6, we purchased two additional compounds, termed
ES-1 and ES-2 (Erv1-SAR), for an abbreviated structure-activity relationship (SAR) study
(Figure 1A). ES-2, but not ES-1 (unpublished data), inhibited Erv1 function in the in vitro
assay with an IC50 of 2.2 μM (Figure 1D). When included in the import assays, ES-2
mirrored MitoBloCK-6 in its ability to impair import, but ES-1 had no effect (Figure 2,
S3C,D). Thus, ES-2 and MitoBloCK-6 seem to specifically inhibit Erv1 function, but ES-1,
like 3,5-dichlorosalicylaldehyde, did not abrogate Erv1 function.
To verify that mitochondrial Erv1 is the target of MitoBloCK-6, an increased abundance of
Erv1 should require an increased MitoBloCK-6 concentration to inhibit protein import.
Previously, we designed a yeast strain in which Erv1 with a C-terminal hexahistidine tag
(designated [a2up]Erv1) was expressed from a high copy plasmid (Dabir et al., 2007).This
strain contained an approximate 5-fold increase in Erv1 with no aberrant phenotypes
detected. The import of Mia40, Cmc1, and AAC proteins was tested in isolated WT and
[a2up]Erv1 mitochondria. For Mia40 and Cmc1, the concentration of MitoBloCK-6 that was
required to inhibit import increased from 10 μM to 50 μM (Figure 4A and 4B). A similar
trend was detected for AAC import, with a concentration increase from 15 μM to 30 μM
(Figure 4C). Combined, the data strongly support that Erv1 is the target of MitoBloCK-6.
To evaluate the cell-based activity of MitoBloCK-6, we also determined the MIC50 with the
Δpdr5Δsnq2 yeast strain in which the genes for the multi-drug resistance pumps PDR5 and
SNQ2 were disrupted in the wild-type strain (Duncan et al., 2007; Hasson et al., 2010).
Deletion of these pumps increases the steady state intracellular concentration of drugs in
yeast. The MIC50 was 15.2 μM (Figure 4D), which is similar to the IC50 concentration that
inhibited protein import. As in the import assays (Figure 4A-C), we measured the MIC50
with the Δpdr5Δsnq2 strain overexpressing Erv1 from a high copy plasmid (Dabir et al.,
2007). The MIC50 increased to 28.3 μM when Erv1 was overexpressed (Figure 4E).
Mitochondria are not Damaged by MitoBloCK-6
A potential mechanism by which MitoBloCK-6 could alter protein translocation is to
nonspecifically permeabilize membranes, resulting in the release of mitochondrial proteins,
particularly from the IMS. We have previously shown that MitoBloCK-2, an inhibitor of the
TIM22 import pathway, nonspecifically permeabilizes mitochondrial membranes (Hasson et
al., 2010). We incubated energized mitochondria with 1% DMSO or MitoBloCK-6 followed
by centrifugation. Released proteins were recovered in the supernatant fraction and analyzed
by Coomassie staining for the collective release of proteins (Figure S4A) and by
immunoblot assay for key proteins (Figure S4B). The results from Coomassie staining
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indicated that MitoBlock-6 did not alter mitochondrial membrane integrity, because proteins
were not released into the supernatant fraction (Figure S4A). Similarly, immunoblot analysis
showed that marker proteins aconitase (matrix), AAC and Tim54 (inner membrane), and
IMS proteins Mia40, Ccp1, and cyt c were not released with MitoBloCK-6 or DMSO
treatment (Figure S4B).
Another potential mechanism by which MitoBloCK-6 may disrupt protein translocation is
indirect, by dissipation of the membrane potential (Δψ) or disruption of oxidative
phosphorylation, both of which can be measured with a Clark-type oxygen sensing electrode
(Figure S4C) (Claypool et al., 2008). Isolated mitochondria were incubated in a 0.5 ml
chamber at 25°C with an oxygen electrode and respiration was initiated with NADH. The
measured oxygen consumption rate was indicative of well-coupled mitochondria. The
subsequent addition of DMSO vehicle or MitoBloCK-6 did not alter the oxygen
consumption rate. As a control, mitochondria were treated with the protonophore carbonyl
cyanide m-chlorophenylhydrazone (CCCP) and respiration increased drastically, indicative
of uncoupled mitochondria (Figure S4C). Taken together, MitoBloCK-6 does not alter
mitochondrial function or disrupt mitochondrial integrity and functions biochemically as a
specific inhibitor of Erv1.
MitoBloCK-6 Impairs Substrate Oxidation
To determine how MitoBloCK-6 inhibited Erv1 function, we investigated whether
MitoBloCK-6 altered Erv1 interactions with partner proteins in isolated mitochondria
(Figure 5A). MitoBloCK-6 was preincubated with mitochondria isolated from the Erv1-His
strain followed by solubilization in 1.0% digitonin and Erv1-His was purified with Ni+2
agarose. In DMSO treated cells, a small fraction of the Mia40 and cyt c co-purified with
Erv1, as reported previously (Tienson et al., 2009). However, in the presence of
MitoBloCK-6, binding of Mia40 and cyt c to Erv1 was decreased by 75% and 95%
respectively (Figure 5A).
If MitoBloCK-6 interferes with Mia40-Erv1 binding, then the oxidation of substrates may be
inhibited in vitro. We therefore evaluated Tim13 oxidation and subsequent production of
H2O2 in vitro (Figure 5B) (Tienson et al., 2009). Erv1 was preincubated with DMSO or
MitoBloCK-6 for 1 h at 25°C. Then, the oxidation of Tim13 was reconstituted by incubating
reduced Tim13 with catalytic amounts of Erv1 and Mia40 in an aerobic environment.
Oxidation was monitored over a time course by the addition of 4-acetamido-4-
maleimidylstilbene-2, 2-disulfonic acid (AMS) followed by non-reducing SDS-PAGE and
immunoblot analysis with antibodies against Tim13. AMS addition causes an increase in
molecular mass of 0.5 kDa per addition to a cysteine residue. In the presence of DMSO,
reconstitution proceeded normally and approximately 80% was oxidized after three hours.
By contrast, only 15% of Tim13 was oxidized in the presence of MitoBloCK-6 (Figure 5B).
As Tim13 was oxidized, H2O2 production was monitored using the Amplex Red-HRP assay
(Figure 5C) (Tienson et al., 2009). The addition of MitoBloCK-6 caused a significant
decrease in H2O2 production compared to the control reactions. We also tested the oxidation
of Cmc1 (Horn et al., unpublished data), a substrate of Mia40/Erv1 pathway, with Erv1
(Figure 5D) and ALR (Figure 5E). An increase in MitoBloCK-6 concentration correlated
with a dose-dependent decrease in H2O2 production. Thus, MitoBloCK-6 specifically blocks
the oxidation of Tim13 and Cmc1 in vitro for both Erv1 and ALR.
As an additional test for MitoBloCK-6 inhibition of Erv1 oxidase activity, we measured the
oxygen consumption rate by Erv1 with an oxygen electrode in the presence of excess DTT
(Dabir et al., 2007). When Erv1 was added alone or with DMSO, the oxygen consumption
rate was similar (Figure S4D). By contrast, the addition of MitoBloCK-6 resulted in a
concentration-dependent decrease in the oxygen consumption rate. Results from these
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analyses show that MitoBloCK-6 selectively inhibits Erv1 and ALR oxidase activity in
vitro.
MitoBloCK-6 Inhibits ALR Function in Vertebrate Mitochondria
The long-term goal in developing the MitoBloCK compounds is to adapt them for studies in
vertebrate mitochondria, such as recapitulating biochemical phenotypes similar to those in
cells derived from patients with mutations in ALR (Di Fonzo et al., 2009). In addition,
MitoBloCK-6 may be useful for studies of apoptosis, iron sulfur cluster and heme export
(Dabir et al., 2007), and cell differentiation (Todd et al., 2010b), because ALR has been
implicated in these pathways. Since MitoBloCK-6 inhibits ALR oxidase activity in vitro, we
asked whether MitoBloCK-6 disrupts mitochondrial function in mammalian cells by
investigating mitochondrial morphology, a general readout for mitochondrial defects. HeLa
cells were transiently transfected with mitochondrial matrix targeted Su9-EGFP and co-
labeled with Mitotracker-Red (Figure S5A). Cells were treated with 50 μM MitoBloCK-6
for 12-16 h and mitochondrial morphology and integrity was visualized by microscopy. In
cells treated with DMSO, Su9-EGFP co-localized with Mitotracker staining and the
mitochondrial network was distributed as in the untreated cells. However, the addition of
CCCP caused the mitochondrial network to collapse around the nucleus. MitoBloCK-6
addition did not disrupt the mitochondrial network (Figure S5A), even at concentrations up
to 100 μM MitoBloCK-6 (unpublished data). We also examined cell viability with a 1-(4, 5-
dimethylthiazol)-3, 5-diphenylformazan (MTT) assay (Figure S5B). MitoBloCK-6 (100
μM) did not significantly reduce cell viability. In addition, treatment of HEK293 cells with
MitoBloCK-6 showed similar results (unpublished data). Because Erv1 passes electrons to
cyt c, ALR may play a role in apoptosis in mammalian cells. Therefore, we queried
specifically whether cyt c was released in cells exposed to MitoBloCK-6 (Figure S5C). Cells
incubated with a positive control, staurosporine, showed cyt c release and detection in the
cytoplasmic fraction as an indication of apoptosis. However, 50 μM MitoBloCK-6 treatment
for 12-16 h failed to initiate cyt c release (Figure S5C). Whereas MitoBloCK-6 inhibits ALR
function in vitro, this inhibitory activity is surprisingly lacking in HeLa and HEK293 cells
ALR was identified in a set of common genes that are enriched in embryonic, neuronal, and
hematopoietic stem cells (Ivanova et al., 2002; Ramalho-Santos et al., 2002), and ALR has a
pro-survival role in maintaining -hESCs (Todd et al., 2010a). Thus, ALR may have a
specific and different role in hESCs and iPSCs than in differentiated cells, such as HeLa and
HEK293 cells. Therefore, we determined whether MitoBloCK-6 affected hESC survival.
HSF1 hESCs and normal human dermal fibroblasts (NHDFs), which represent a
differentiated cell type, were exposed with 20 μM MitoBloCK-6 or 0.1% DMSO and
visualized using brightfield microscopy (Figure S6A), including staining with Coomassie
brilliant blue to visualize colony morphologies (Figure S6B)(Mochizuki and Furukawa,
1987). MitoBloCK-6 exposure resulted in marked HSF1 cell death, whereas DMSO
exposure did not cause cell death or alter overall colony morphology. MitoBlock-6 may
trigger stem cell apoptosis. Release of cyt c was examined in HSF1 cells exposed to
MitoBloCK-6 (Figure 6A) using antibodies against cyt c and visualized by fluorescence
microscopy (Waterhouse et al., 2001). MitoBloCK-6 addition resulted in a shift in cyt c
localization from mitochondria (marked with Tomm20) into the cytosol (shown as diffuse
staining that did not overlap with Tomm20 staining). SAR compound ES-2, but not ES-1,
also caused cyt c release from mitochondria. Quantification indicated that the number of
cells in which cyt c was released was similar with addition of MitoBloCK-6, ES-2 or
Actinomycin D, a known apoptosis inducer (Figure 6B). In contrast, treatment with the
broad caspase inhibitor Q-VD-OPH and the vehicle 0.1% DMSO did not alter mitochondrial
morphology or cause cyt c release. In addition, downstream events in apoptosis, poly ADP-
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ribose polymerase (PARP) and caspase-3 cleavage, were also detected with MitoBloCK-6
exposure (Figure 6C).
To support that MitoBloCK-6 specifically inhibited the survival of hESCs and not of
differentiated cells, HSF1 cells were induced to differentiate with 10 μM retinoic acid
followed by MitoBloCK-6 exposure (Figure S6). Again, the images show that colony
morphology remained intact when HSF1 cells were differentiated with retinoic acid
treatment and cells did not die. To assess the earliest time point at which MitoBloCK-6
perturbed hESC viability, a time course assay was performed and hESCs were stained for
alkaline phosphatase activity (Shamblott et al., 1998). hESC viability started to decline after
5 hours post treatment (Figure 6D). 20 μM SAR compounds ES-1 and ES-2 were applied to
hESCs and stained for alkaline phosphatase activity. Whereas ES-1 had no effect on cell
growth , ES-2 inhibited cell growth similar to MitoBloCK-6 (Figure 6E) . Taken together,
MitoBloCK-6 does not inhibit mitochondrial function in differentiated cells, but hESCs
were susceptible to MitoBloCK-6 and apoptosis was induced. The data suggest a keyrole for
ALR in hESC maintenance and show that MitoBloCK-6 is a small molecule reagent that
identifies this function.
Having characterized the effects of MitoBloCK-6 in vitro and in primary cell culture
systems, we applied MitoBloCK-6 to developing zebrafish embryos, which is a useful in
vivo vertebrate model. The effect of MitoBlock-6 on mitochondrial function and zebrafish
development was tested using previously established parameters (Mendelsohn et al., 2006;
Murphey and Zon, 2006). Zebrafish embryos were placed in either 1% DMSO or 2.5 μM
MitoBloCK-6 at 3 h post fertilization (hpf) and allowed to develop until 72 hpf. Higher
concentrations of MitoBloCK-6 were toxic to the fish. MitoBloCK-6 but not DMSO
incubated embryos displayed ventral curvature of the body and cardiac edema (Figure
7A,B). Furthermore, we also treated fish with MitoBloCK-6 from 3 to 24 hpf, followed by
removal of MitoBloCK-6, and the zebrafish embryos were identical to those exposed to
DMSO at 72 hpf, indicating that the effects of MitoBloCK-6 are reversible (unpublished
data). Because ALR may play a role in FeS cluster assembly and export (Lange et al., 2001),
erythropoiesis may be defective (Shaw et al., 2006). Therefore, embryos were stained with
o-dianisidine, which binds to heme (Lumsden et al., 2007), as a method to visualize
hematopoietic development. Whereas embryos exposed to 1% DMSO or MitoBloCK-6
showed normal hematopoiesis, embryos treated with MitoBloCK-6 showed erythrocyte
pooling along the yolk sac prior to entering the lower chamber of the heart and an absence of
red blood cells in the tail (Figure 7D,E). To assess if the observed phenotypes were caused
by ALR inhibition via MitoBloCK-6, 1-cell embryos were also injected with 4 ng of an
ATG morpholino targeted to ALR (Figure 7C,F). This morpholino prevents ALR translation
in embryos. The phenotypes observed from the morpholino–injected embryos were identical
to that of MitoBlock-6 exposure, suggesting that ALR is targeted. Cardiac development was
also investigated in a transgenic zebrafish line in which DsRed is targeted to mitochondria
under control of the heart specific cardiac myosin light chain promoter cmlc2 (Figure 7G-I)
(Shu et al., 2007). Cardiac development at day 3 in embryos exposed to DMSO was similar
to that of wild-type fish in that the heart is looped and the mitochondria are also very bright
(Figure 7G-I). In contrast, MitoBloCK-6 exposure retarded cardiac development in that the
hearts failed to loop by day 2, instead becoming stringy and extended. In addition, the
mitochondria were less fluorescent (Figure 7H), which is likely indicative of dysfunctional
mitochondria. This developmental defect is supported by a decreased heart rate of 50% and
25% in embryos treated with MitoBloCK-6 and the ALR morpholino, respectively.
To confirm that the target of MitoBloCK-6 in vivo is indeed ALR, embryos were treated
with sub-optimal concentrations of MitoBloCK-6 (1 or 2 μM) and the ATG morpholino (1
or 2 ng) in different combinations (Figure S7). Lower concentrations of either MitoBloCK-6
Dabir et al. Page 8













or ATG morpholino did not impair development; cardiac tissue was relatively normal and
Ds-Red fluorescence marking mitochondria was similar to the fish treated with 1% DMSO.
As zebrafish were treated with 2 μM MitoBloCK-6 and 1-2 ng of ATG morpholino, defects
in development were additive. Specifically, the embryos displayed cardiac edema, and
decreased fluorescence in cardiac tissue; this phenotype was similar to that in embryos
treated with either 2.5 μM MitoBloCK-6 or 4 ng ATG morpholino (Figure 7). Taken
together, the data strongly suggest that MitoBloCK-6 specifically targets and blocks ALR
function in zebrafish, which is marked by impaired cardiac development.
Discussion
We identify MitoBloCK-6 as a selective inhibitor of the Mia40/Erv1 redox-mediated import
pathway. Based on the assay in which oxidation of substrate DTT by Erv1 was inhibited, the
mechanism by which MitoBloCK-6 may attenuate Erv1 activity is to potentially interfere
with binding or electron transfer between Mia40, cyt c, and/or oxygen. MitoBloCK-6 is a
stable compound. The hydroxyl group at the ortho-position likely stabilizes the compound
(Crugeiras et al., 2009), and a similar class of molecules has been identified in a small
molecule screen for inhibitors of Type III secretion (Nordfelth et al., 2005).
Import of CX9C proteins was reduced more than CX3C protein Tim8. Pfanner and
colleagues have shown that a ternary complex is formed by the substrate, Mia40, and Erv1
(Stojanovski et al., 2008); MitoBloCK-6 may potentially interfere with the formation of this
ternary complex in a substrate-specific manner. Strong inhibition of Mia40 import by
MitoBloCK-6 was also unexpected, because full-length Mia40 in yeast uses the TIM23
pathway (as in Figure 2A), but a truncated version, similar to human Mia40, that contains
the core cysteine residues uses the Mia40/Erv1 pathway (Chacinska et al., 2008). That
MitoBloCK-6 blocks Mia40 import suggests that the Erv1 pathway may be important for
coordinating disulfide assembly in the imported Mia40, because mia40 mutants with
cysteine mutations that prevent correct disulfide bond formation are not viable (Terziyska et
al., 2009). Surprisingly, import of substrates of the TIM22 pathway (AAC and Tim23) was
also reduced, which suggests a broader role for the Mia40/Erv1 pathway in protein
translocation. The potential role of Erv1 in the TIM22 pathway may be difficult to dissect
with yeast mutants; a subset of yeast mutants did not show a defect in the carrier import
pathway (Mesecke et al., 2005; Rissler et al., 2005), whereas our import studies with erv1
mutants resulted in general pleiotropic defects in import (unpublished data). Redox
regulation seems to be important in the TIM22 pathway, because the small Tim proteins
may undergo redox regulation and the cysteine-rich protein Hot13 may also participate
(Curran et al., 2004). Alternatively, MitoBloCK-6 inhibition of Erv1 may change the redox
potential of the IMS, which may alter import ability of the small Tim proteins. Additional
experiments will be required to determine how MitoBloCK-6 specifically alters the TIM22
pathway.
ALR has a Key Function in hESC Maintenance and Zebrafish Development
Our strategy of screening with the yeast protein Erv1 was also constructive because
MitoBloCK-6 inhibited the human homolog ALR with an improved IC50 of 700 nM. High-
resolution crystallography and NMR studies of four Erv1 family proteins, Arabidopsis
thaliana Erv1 (Vitu et al., 2006), rat ALR (Wu et al., 2003), human ALR (Banci et al.,
2011), and yeast Erv2 (Gross et al., 2002), reveal that the structure is highly conserved.
Thus, our screen has produced small molecules that work across species. This also has been
shown in an in vivo screen in which we determined that MitoBloCK-1 of yeast Tim10 also
inhibited Tim10 in mammalian mitochondria (Hasson et al., 2010). Furthermore, Nunnari
and colleagues identified mdivi-1 as an inhibitor of the yeast fission component Drp1
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(Cassidy-Stone et al., 2008). mdivi-1 also abrogates mammalian Drp1 and retards apoptosis
by preventing mitochondrial outer membrane permeabilization.
Whereas MitoBloCK-6 inhibits activity of the Erv1 family in vitro, a surprising finding was
that MitoBloCK-6 did not inhibit growth or function of differentiated cells in vivo. An initial
reason may be that a factor in the media inhibited MitoBloCK-6 action. However, several
types of media were tested, including the permissive hESC media with differentiated cells,
MitoBloCK-6 remained inactive. In contrast, MitoBloCK-6 specifically induced apoptosis in
hESCs, suggesting ALR may have a distinct role in pluripotent stem cell maintenance.
Published studies support a role for ALR in stem cells, because ALR expression is enriched
in embryonic, neuronal, and hematopoietic stem cells (Ivanova et al., 2002; Ramalho-Santos
et al., 2002). ALR has been reported to have a pro-survival role in maintaining mouse
pluripotent embryonic stem cells by interacting with Drp1 (Todd et al., 2010a). However,
Drp1 is a cytosolic protein mediating mitochondrial fission and it is not apparent how IMS-
localized ALR associates with Drp1; our data supports the model that ALR inactivation by
MitoBlock-6 results in cyt c release and the mitochondrial network collapses as a
consequence of apoptosis (Parone et al., 2006). We and others have shown that Erv1 and
ALR shuttle electrons to cyt c (Bihlmaier et al., 2007; Dabir et al., 2007; Farrell and Thorpe,
2005). In differentiated cells, approximately 85% of the cyt c population is distributed in the
cristae in association with the respiratory complexes and 15% is located in the IMS in the
region between the inner and outer membrane (Bernardi and Azzone, 1981); this 85%
population of cyt c is released from the cristae during apoptosis in differentiated cells
(Scorrano et al., 2002). However, hESC mitochondria lack numerous cristae and display
decreased respiration compared to differentiated cells (Zhang et al., 2011), so the population
of cyt c that associates with ALR may be the critical pool that is released during apoptosis.
As a result of our preliminary finding, MitoBloCK-6 is an excellent tool to understand the
contribution of mitochondrial to pluripotent stem cell function and differentiation. In
addition, MitoBloCK-6 may be important in translational strategies to remove pluripotent
hESCs that “fail-to-differentiate” in hESC transplantation studies. Removal of hESCs prior
to transplantation in patients is important because hESCs induce teratomas in the wrong
environment (Tang et al., 2011). Additional studies are ongoing to understand how
MitoBloCK-6 induces apoptosis in hESCs.
In contrast to differentiated culture cells, zebrafish provide a powerful model system for
characterizing ALR function because cells are not transformed and are in their normal
physiologic setting of cell-cell and cell-extracellular matrix interactions (Murphey and Zon,
2006). The embryos are also in simple buffered water, so MitoBloCK-6 uptake may be
enhanced. Defects in mitochondrial biogenesis in zebrafish display varied phenotypes.
Mutations in the Tomm22 import component result in defects in liver development (Curado
et al., 2010) and mutations in Fe-S cluster biogenesis typically impact erythropoiesis (Shaw
et al., 2006; Wingert et al., 2005). Indeed, MitoBloCK-6 also elicited gross morphologic and
cardiac defects in zebrafish that were akin to ALR downregulation. Overall, characterization
of MitoBloCK-6 supports that the chemical approach is valid for developing probes to study
protein translocation and understand the role of protein import in development.
Materials and Methods
High-throughput screen for Erv1 modulators
The primary chemical screen used fresh recombinant Erv1( in buffer 30 mM Hepes, pH 7.4,
100 mM NaCl, 1 mM EDTA) at a concentration of 10 μM, which was expressed as
described previously. A Titertek multidrop (Beckman Coulter) was used to dispense 25 μl
Erv1 or 25 μl of catalytically inactive enzyme Erv1C133S into wells of a clear bottom 384-
well plate (Greiner Bio One). A Biomek FX (Beckman Coulter) was used to pin transfer 0.5
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μl of compound from 1 mM stock or DMSO to respective wells. Approximate screening
concentration was 12.5 μM. After completed compound transfer, all plates were incubated
at 25°C in a humidified incubator for 1 hour. A Titertek multidrop was used to dispense 15
μl of Amplex Red-horseradish peroxidase (HRP) (Sigma) mix into all wells of the 384-well
plate. The final concentration of Amplex Red and HRP were 46 μM and 0.092 U/ml,
respectively. The Amplex Red-HRP solution was shielded from light during the entire
experiment. The plates were incubated for an additional 10 min and then 15 μl of the
substrate DTT (20 μM) was added to initiate the reduction of O2 to H2O2. The plates were
incubated for 12 minutes to achieve a maximal signal-to-noise ratio in the kinetic liner
range. Plates were then read at an endpoint using an excitation wavelength of 545 nm and an
emission wavelength of 590 nm. All operations were performed by an automated plate
scheduler to ensure consistency across the screening run. We chose compounds that
inhibited Erv1 activity by greater than 50%. Using a similar screening methodology as
above, hit compounds were reconfirmed. Compounds that were available were ordered from
Asinex and Chembridge and assayed for IC50 using a similar automated technique in 384-
well plates as previously described. Serial dilutions of purchased compounds were
performed with robotic automation in 100% DMSO. Subsequently, compounds were pinned
into assay plate wells containing 10 μM Erv1, Erv2, or ALR.
Assays in hESCs
The hESC line hSF1 was cultured in Stem Pro SFM (Gibco) supplemented with 10 ng/ml
bFGF on Matrigel (BD Biosciences) coated plates under 5% CO2, 95% air. Differentiation
involved culturing cells in Stem Pro SFM with 10 μM retinoic acid (Acros Organics) for 4
days. Cells were treated with the indicated concentration of the MitoBloCK compounds or
0.1% DMSO as a control. For cytochrome c release analysis using microscopy, cells were
exposed to 20 μM actinomycin D (Sigma), MB-6, ES-1, or ES-2 with 25 μM broad caspase
inhibitor Q-VD-OPH (EMD Millipore) (Caserta et al., 2003). Treatment with Q-VD-OPH
and 0.1% DMSO alone or in combination did not affect cell morphology. Following
treatment, cells were fixed with 3.7% formaldehyde for indirect immunofluorescence study
or lysed with Triton buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100,
1mM EDTA) for analysis by SDS-PAGE. Bright field images were acquired with Exi Blue
(QImaging). Immunofluorescent images were acquired with a 63x oil immersion objective
on an LSM 5 PASCAL Laser Scanning Microscope (Carl Zeiss). Antibodies against cyt c
(BD Pharmingen), Tomm20 (Santa Cruz), cleaved caspase-3 (Cell Signaling) and poly
(ADP-ribose) polymerase (Cell Signaling) were purchased from the indicated vendors.
Nuclei were visualized by Hoechst (0.12 μg/ml) staining after straining. Alkaline
phosphatase activity staining was performed with the leukocyte alkaline phosphatase kit
(Sigma) as per manufacturer’s protocol. Coomassie brilliant blue staining was performed by
staining cells with Coomassie brilliant blue solution (0.25% Coomassie brilliant blue R250,
45% Methanol, 10% Acetic acid) for 1 hour at room temperature. Cells were washed with
phosphate-buffered saline followed by visualization as described above.
Statistical analysis
Quantitative analysis was performed in GraphPad Prism 5 software unless otherwise stated.
Statistical tests for significant deviation between samples were performed using One-way
ANOVA followed by Bonferroni’s post test. The alpha threshold for significance was < 0.05
for all tests.
Assays
MitoBloCK-6 was analyzed using a battery of established in vitro, yeast, mammalian cell-
based, and zebrafish assays. These are described in detail in the Supplemental Data. Yeast
strains listed in Table S1.
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Small molecule MitoBloCK-6 inhibits Erv1/ALR and thus mitochondrial protein import
MitoBloCK-6 impairs import of both Mia40/Erv1 and TIM22 pathways
MitoBloCK-6 selectively kills embryonic stem cells but not differentiated lineages.
ALR influences zebrafish cardiac development
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Figure 1. MitoBloCK-6 inhibits Erv1 activity
(A) The structure of MitoBloCK-6, Erv1 SAR compound-1 (ES-1) and compound-2 (ES-2),
and 3,5-dichlorosalicyclaldehyde. (B) IC50 analysis of MitoBloCK-6 in the in vitro Erv1
activity assay. 10 μM Erv1 was incubated with varying concentrations of MitoBloCK-6 as
described for the chemical screen (C) As in ‘B’, IC50 analysis with 3,5-
dichlorosalicylaldehyde and Erv1. (D) As in ‘B’, IC50 analysis with ES-2 and Erv1. (average
± SD, n = 3)
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Figure 2. MitoBloCK-6 inhibits the import of substrates of the Mia40/Erv1 pathway
Radiolabeled precursors were imported into WT mitochondria in the presence of 25 or 50
μM MitoBloCK-6, 50 μM SAR compounds or the control 1% DMSO. Non-imported
precursor was removed by protease treatment. A 10% standard (Std) from the translation
reaction is included. Precursors included (A) Mia40, (B) Cmc1, (C) Cox19, and (D) Tim8. A
10% standard (Std) from the translation reaction is included. Import reactions were
quantitated using a BioRad FX Molecular Imager and the affiliated Quantity 1 software;
100% was set as the amount of precursor imported into WT mitochondria at the endpoint in
the time course.
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Figure 3. MitoBloCK-6 inhibits the import of substrates of the TIM22 import pathway but not
the TIM23 import pathway
As in Figure 2, import assays were performed. Precursors included TIM22 import substrates
(A) Tim23 and (B) AAC and (C) TIM23 substrate Su9-DHFR. Aliquots were removed at
the indicated time points and samples were treated with carbonate extraction to confirm that
Tim23 and AAC were inserted into the inner membrane. (D) AAC was imported in the
presence of DMSO or 25 μM MitoBloCK-6, aliquots were removed at indicated time points
and samples were subjected to Blue-Native PAGE analysis followed by autoradiography
(left panel) or immunoblotted with antibodies against Tom40 (right panel). AAC2 marks the
AAC dimer and AAC/TOM marks AAC that accumulates in the TOM complex. % import
calculated as in Figure 2.
Dabir et al. Page 19













Figure 4. Inhibition of import by MitoBloCK-6 is dependent on the concentration of Erv1 in
mitochondria
Import assays of precursors (A) Mia40, (B) Cmc1 and (C) AAC were performed as
described in Figure 2 into mitochondria derived from wild-type yeast (WT) or yeast
overexpressing Erv1 with a hexahistidine tag ([a2up]Erv1) (Dabir et al., 2007). The
concentration of MitoBloCK-6 was varied from 5 to 50 μM as indicated. A 10% standard
(Std) from the translation reaction was included. (D) MIC50 analysis of the WT yeast strain
lacking the drug pumps (Δpdr5 Δsnq2) with varying concentrations of MitoBloCK-6.
(average ± SD, n = 6) (E) As in ‘D’, MIC50 analysis of the Δpdr5 Δsnq2 yeast strain that
overexpresses Erv1-His from a high-copy plasmid ([a2up]Erv1). (average ± SD, n = 6)
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Figure 5. MitoBloCK-6 impairs substrate oxidation in vitro and disrupts Erv1 binding
(A) Mitochondria from a strain expressing C-terminal histidine-tagged Erv1 were incubated
with 50 μM MitoBloCK-6 or 1% DMSO for 30 min at 25°C followed by solubilization in
1% digitonin buffer. As a control, 100 μg of extract was withdrawn (T), and 500 μg lysate
was incubated with Ni+2-agarose beads. The beads were washed and bound proteins (B)
were eluted with SDS-PAGE sample buffer. To test effectiveness of binding, 100 μg of the
unbound protein fraction (S) was also included. Proteins were analyzed by immunoblotting
with polyclonal antibodies against Mia40, Erv1, and cyt c. (B) Recombinant Erv1 was
preincubated with MitoBloCK-6 or 1% DMSO for 1 hr at 25°C and then Erv1 (1 μM) was
incubated with reduced Tim13 (15 μM) and Mia40 (1 μM) in a time course assay (Tienson
et al., 2009). Aliquots were removed at the indicated times and free thiols on Tim13 were
modified with AMS addition. Oxidized and reduced Tim13 were detected by non-reducing
SDS-PAGE and immunoblotting with antibodies against Tim13. (C, D, E) The same
reconstitution assay was performed as in ‘B’ with reduced Tim13 (C) or reduced Cmc1
(D,E) or mammalian ALR (E) and H2O2 production was monitored over a 30-min time
period with the indicator Amplex Red and displayed as pmol H2O2. (1-way ANOVA, n = 3)
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Figure 6. MitoBloCK-6 induces apoptosis in hESCs
(A) HSF1 cells were treated with 20 μM MitoBloCK-6, ES-1, or ES-2 for 8 hours. As a
positive control, apoptosis was induced in cells by treatment with 20 μM actinomycin D
(ActD) for 8 hours. Downstream caspases were inhibited by simultaneous addition of 25 μM
Q-VD-OPH (caspase inhibitor) for 8 hours. Cells were fixed and analyzed by
immunofluorescence microscopy using antibodies against cyt c (green) and Tomm20 (Red).
Merged images are also depicted in panels with Hoescht staining (blue) to mark nuclei.
Scale bar, 20 μm. (B) Quantification of data obtained in (A) and represented as % of cells
that lost the mitochondrial cyt c staining at 5h (white bars) or 8h (solid black bars) but
retained Tomm20 staining. Data was collected from three independent experiments. Error
bars represent standard deviation. (average % ± SD; n = 4) . (C) As in ‘A’, HSF1 cells were
treated with 20 μM MitoBloCK-6 or 20 μM ActD for the indicated time. Whole cell
extracts were analyzed by SDS-PAGE and immunoblotted with antibodies for caspase-3
fragment and PARP. Tomm40 was included as a loading control. (D) As in ‘A’, HSF1 cells
were treated with 20 μM MitoBloCK-6 for the indicated times followed by staining for
alkaline phosphatase activity. Scale bar, 500 μm. (E) Analysis of alkaline phosphatase
activity in HSF1 cells after treatment with 0.1% DMSO, 20 μM MitoBloCK-6 ,20 μM ES-1
or 20 μM ES-2 for 16 hours. Scale bar, 500 μm.
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MitoBloCK-6 treatment impairs cardiac development in zebrafish. Embryos (3 hpf) were
treated with 2.5 μM MitoBloCK-6 (B, E, H) or 1% DMSO (A,D,G) or embryos were
injected with an ATG morpholino against ALR (C,F). Development was visualized by
microscopy at 72 hpf (A-C). Erythrocytes were visualized by o-dianisidine staining at 72 hpf
(D-F); arrows indicate regions of red blood cell accumulation in wild-type fish.
Fluorescence microscopy of zebrafish hearts (72 hpf) that contained a mitochondrial-
targeted DsRed included embryos treated with 1% DMSO (G), 2.5 μM MitoBloCK-6 (H),
and buffer only (I).
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